Evaluation of a new hydroxyethyl starch solution (HES 130/0.4) in patients undergoing preoperative autologous blood donation

Journal of Clinical Anesthesia

Volumn 13, Issue 7, 2001, Pages 486-490

  Kasper, Stefan Mario ^a,b   Strömich, Andrea ^a   Kampe, Sandra ^a   Radbruch, Lukas ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Department of Anesthesiology ^*  (Germany)

Author keywords

Colloids, hydroxyethyl starch: pharmacology; Hemodynamics; Patient safety

Indexed keywords

ALANINE AMINOTRANSFERASE; HETASTARCH; PLASMA SUBSTITUTE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD DONOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; INFUSION; MAJOR CLINICAL STUDY; MALE; MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TINNITUS; TISSUE PRESERVATION;

ADULT; AGED; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION, AUTOLOGOUS; DOUBLE-BLIND METHOD; FEMALE; HEMODYNAMIC PROCESSES; HETASTARCH; HUMANS; MALE; MIDDLE AGED; SOLUTIONS;

EID: 0034750067     PISSN: 09528180     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-8180(01)00311-7     Document Type: Article

References (25)

1. Treib J, Baron JF, Grauer MT, Strauss RG: An international view of hydroxyethyl starches. Intensive Care Med 1999;25:258-68.
2. Warren BB, Durieux ME: Hydroxyethyl starch: safe or not? Anesth Analg 1997;84:206-12.
3. Sirtl C, Laubenthal H, Zumtobel V, Kraft D, Jurecka W: Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. Br J Anaesth 1999;82:510-5.
4. Treib J, Haass A, Pindur G: Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 1997;78:974-83.
5. Waitzinger J, Bepperling F, Pabst G, Opitz J, Fackelmeyer A, Boldt J: Effect of a new hydroxyethyl starch (HES) specification (6% HES 130/0.4) on blood and plasma volumes after bleeding in 12 healthy male volunteers. Clin Drug Invest 1999;17:119-25.
6. Waitzinger J, Bepperling F, Pabst G, Opitz J, Müller M, Baron JF: Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification (HES 130/0.4) after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 1998;16:151-60.
7. Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR: Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography. Anesth Analg 1998;87:989-93.
8. Boldt J, Lehmann A, Römpert R, Haisch G, Isgro F: Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2000;14:264-8.
9. Entholzner EK, Mielke LL, Calatzis AN, Feyh J, Hipp R, Hargasser SR: Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher molecular weight. Acta Anaesthesiol Scand 2000;44:1116-21.
10. ®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000;47:1207-15.
11. ®, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001;92:855-62.
12. The National Blood Resource Education Program Expert Panel: The use of autologous blood. JAMA 1990;263:414-7.
13. Br Committee for Standards in Haematology Blood Transfusion Task Force: Guidelines for autologous transfusion. I. Pre-operative autologous donation. Transfusion Med 1993;3:307-16.
14. Bland M: An Introduction to Medical Statistics, 2d ed. Oxford, UK: Oxford Medical Publications, 1996:126-7.
15. Treib J, Haass A, Pindur G, et al: HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation, and elimination kinetics. Thromb Haemost 1995;74:1452-6.
16. Bepperling F, Opitz J, Leuschner J: HES 130/0.4, a new HES specification: tissue storage after multiple infusions in rats [Abstract]. Crit Care 1999;3 (Suppl 1):76.
17. Spiess BD, Sassetti R, McCarthy RJ, Narbone RF, Tuman KJ, Ivankovich AD: Autologous blood donation: hemodynamics in a high-risk patient population. Transfusion 1992;32:17-22.
18. Kasper SM, Dahlmann H, Mellinghoff H, ElleringJ, Baumann M, Buzello W: Lactated Ringer's solution versus hydroxyethyl starch for volume replacement in autologous blood donors with cardiovascular disease: a controlled, randomized trial. Vox Sang 1998; 75:26-31.
19. Kasper SM, Weimbs G, Wassmer G: Isovolaemic volume replacement in autologous blood donors with cardiovascular disease - a randomized, cross-over trial [Abstract]. Anästh Intensivmed 2000; 41:405.
20. Newman BH: Donor reactions and injuries from whole blood donation. Transfusion Med Rev 1997;11:64-75.
21. McVay PA, Andrews A, Kaplan EB, et al: Donation reactions among autologous donors. Transfusion 1990;30:249-52.
22. Graham ID, Fergusson D, Dokainish H, Biggs J, McAuley L, Laupacis A: Autologous versus allogeneic transfusion: patients' perceptions and experiences. Can Med Assoc J 1999;160:989-95.
23. Reimann S, Szépfalusi Z, Kraft D, Luger T, Metze D: Storage of hydroxyethyl starch in the skin causing pruritus. Dtsch Med Wschr 2000;125:280-5.
24. Bothner U, Georgieff M, Vogt NH: Assessment of the safety and tolerance of 6% hydroxyethyl starch (200/0.5) solution: a randomized, controlled epidemiology study. Anesth Analg 1998;86: 850-5.
25. Morgan PW, Berridge JC: Giving long-persistent starch as volume replacement can cause pruritus after cardiac surgery. Br J Anaesth 2000;85:696-9.